Isconova appoints Sven Andréasson as new CEO.
Isconova initiates a collaboration with a leading Russian company within veterinary medicines aimed at developing a rabies vaccine for the Russian market and with marketing rights for Isconova for the rest of the world.
Matrix™ selected as one of three immune-stimulating substances for further studies (pre-IND) in a project to develop therapeutical substances effective against biological warfare or bio-terrorism.
Study shows that Isconova´s Matrix-M is an excellent pandemic influenza vaccine candidate.
Isconova appoints Lena Söderström as new CEO.
Signing an agreement with a major american vaccine development company
Two cornerstone patent applications granted in Europe
Launch of Intervet’s Equilis® Prequenza vaccine for horse flu
US Biodefense research contract awarded
License deal regarding Isconova’s new generation Matrix-M adjuvant with a major vaccine development company relating to human flu and human RSV vaccines
Excellent results from pre-IND safety studies
Long-term contract manufacturing agreement awarded for Matrix-based equine vaccines
Development of Isconova’s new generation ISCOM technology with potent efficacy and much improved safety resulting in three new patent applications
License deal relating to Matrix-based equine vaccine to a major veterinary vaccine development company
Isconova’s operations started